DE69721120D1 - Verwendung von menschlichen Chemokin beta-9 zur Behandlung von Atemnotsyndrom bei Erwachsenen - Google Patents
Verwendung von menschlichen Chemokin beta-9 zur Behandlung von Atemnotsyndrom bei ErwachsenenInfo
- Publication number
- DE69721120D1 DE69721120D1 DE69721120T DE69721120T DE69721120D1 DE 69721120 D1 DE69721120 D1 DE 69721120D1 DE 69721120 T DE69721120 T DE 69721120T DE 69721120 T DE69721120 T DE 69721120T DE 69721120 D1 DE69721120 D1 DE 69721120D1
- Authority
- DE
- Germany
- Prior art keywords
- adults
- treatment
- respiratory distress
- distress syndrome
- human chemokine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1787196P | 1996-05-14 | 1996-05-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69721120D1 true DE69721120D1 (de) | 2003-05-28 |
DE69721120T2 DE69721120T2 (de) | 2003-12-04 |
Family
ID=21785003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69721120T Expired - Fee Related DE69721120T2 (de) | 1996-05-14 | 1997-05-12 | Verwendung von menschlichen Chemokin beta-9 zur Behandlung von Atemnotsyndrom bei Erwachsenen |
Country Status (5)
Country | Link |
---|---|
US (5) | US6290948B1 (de) |
EP (1) | EP0807439B1 (de) |
JP (2) | JPH1053533A (de) |
DE (1) | DE69721120T2 (de) |
DK (1) | DK0807439T3 (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6811773B1 (en) | 1993-12-22 | 2004-11-02 | Human Genome Sciences, Inc. | Human monocyte colony inhibitory factor (M-CIF) polypeptides |
US6488925B2 (en) | 1993-12-22 | 2002-12-03 | Human Genome Sciences, Inc. | Macrophage inflammatory protein-4 (MIP-4) polypeptides |
US6451562B1 (en) | 1993-12-22 | 2002-09-17 | Human Genome Sciences, Inc. | Polypeptides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) polynucleotides |
US6495129B1 (en) | 1994-03-08 | 2002-12-17 | Human Genome Sciences, Inc. | Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3) |
NZ320932A (en) * | 1995-09-29 | 2000-01-28 | Smithkline Beecham Corp | Short forms of chemokine b-8 |
US6713052B1 (en) | 1995-10-24 | 2004-03-30 | Human Genome Sciences, Inc. | Method of mobilizing stem cells with chemokine β-8 |
US6290948B1 (en) * | 1996-05-14 | 2001-09-18 | Smithkline Beecham Corporation | Method of treating sepsis and ARDS using chamohine beta-10 |
US6632425B1 (en) | 1997-03-20 | 2003-10-14 | Human Genome Sciences, Inc. | Chemokine compositions |
US6989435B2 (en) | 1997-09-11 | 2006-01-24 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
US7067117B1 (en) | 1997-09-11 | 2006-06-27 | Cambridge University Technical Services, Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
KR19990042713A (ko) * | 1997-11-27 | 1999-06-15 | 허일섭 | 사람에서 분리한 c 6 베타-케모카인 lkn-1의 cdna 및 재조합 lkn-1의 제조방법 |
AU1824499A (en) * | 1997-12-30 | 1999-07-19 | Chiron Corporation | Human cxc chemokine ((tim-1)) |
US6495128B1 (en) | 1998-11-10 | 2002-12-17 | Human Genome Sciences, Inc. | Human chemokine β-7 deletion and substitution proteins |
US7238711B1 (en) | 1999-03-17 | 2007-07-03 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
EP1348443A4 (de) * | 2000-12-08 | 2005-07-06 | Takeda Pharmaceutical | Kombinationsmedikamente |
MXPA05012099A (es) * | 2003-05-09 | 2006-02-08 | Schering Ag | Tratamiento de enfermedades respiratorias inflamatorias. |
WO2004103294A2 (en) | 2003-05-15 | 2004-12-02 | Tanox, Inc. | Methods and compositions for the prevention and treatment of sepsis |
WO2006063150A2 (en) * | 2004-12-08 | 2006-06-15 | Immunomedics, Inc. | Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer |
JP5583575B2 (ja) | 2007-03-28 | 2014-09-03 | ユニベルシダード デ バルセロナ | 感染症と関連炎症過程の治療のためのタンパク質生成物 |
NZ611269A (en) | 2010-11-19 | 2015-03-27 | Eisai R&D Man Co Ltd | Neutralizing anti-ccl20 antibodies |
AU2017360043A1 (en) | 2016-11-18 | 2019-06-20 | Hospital Clinic De Barcelona | Combined CD6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4897348A (en) * | 1983-08-25 | 1990-01-30 | Sri International | Recombinant materials and methods for producing human connective tissue-activating peptide-III and analogs thereof |
US4897338A (en) * | 1987-08-03 | 1990-01-30 | Allied-Signal Inc. | Method for the manufacture of multilayer printed circuit boards |
CH681625A5 (de) * | 1988-12-08 | 1993-04-30 | Sandoz Ag | |
US5212073A (en) * | 1989-05-12 | 1993-05-18 | Genetics Institute, Inc. | Process for producing human JE cytokine |
US5179078A (en) * | 1989-05-12 | 1993-01-12 | Dana Farber Cancer Institute | Method of suppressing tumor formation in vivo |
DE69020573T3 (de) * | 1989-09-25 | 1999-12-16 | Crc Technology Ltd., London | Verfahren zur wachstumshemmung von stammzellen. |
NZ237202A (en) * | 1990-02-23 | 1994-01-26 | Bristol Myers Squibb Co | Composition containing beta-lactam antibiotic and cationic oligopeptide |
JPH06503710A (ja) * | 1990-09-14 | 1994-04-28 | カイロン コーポレイション | 酵母細胞におけるマクロファージ誘導タンパク質(mip)の発現 |
US5401651A (en) * | 1991-10-16 | 1995-03-28 | Walz; Alfred | DNA encoding ENA-78, a neutrophil activating factor |
US5306709A (en) * | 1991-11-15 | 1994-04-26 | The University Of Pennsylvania | Suppression of megakaryocytopoiesis by macrophage inflammatory proteins |
US5346686A (en) * | 1992-10-05 | 1994-09-13 | Mallinckrodt Medical, Inc. | Labelled interleukin-8 and medical uses thereof |
US5413778A (en) * | 1992-10-05 | 1995-05-09 | The Regents Of The University Of Michigan | Labelled monocyte chemoattractant protein material and medical uses thereof |
US5474983A (en) * | 1993-03-15 | 1995-12-12 | The Research Foundation Of State University Of New York | Method of inhibiting pro-inflammatory mediator release from basophils and mast cells |
US5346685A (en) * | 1993-04-23 | 1994-09-13 | Mobil Oil Corp. | Synthetic porous crystalline MCM-51, its synthesis and use |
JPH0789866A (ja) * | 1993-09-21 | 1995-04-04 | Nippon Kayaku Co Ltd | 感染防御剤 |
JP3677288B2 (ja) * | 1993-12-22 | 2005-07-27 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | マクロファージ炎症蛋白質−3、−4および−1▲下γ▼ |
JPH10500301A (ja) * | 1994-05-16 | 1998-01-13 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | マクロファージ遊走阻止因子−3 |
WO1996005856A1 (en) * | 1994-08-23 | 1996-02-29 | Human Genome Sciences, Inc. | Human chemokine polypeptides |
ES2235172T3 (es) * | 1994-08-23 | 2005-07-01 | Human Genome Sciences, Inc. | Quimioquina humana beta-9. |
WO1996009062A1 (en) * | 1994-09-23 | 1996-03-28 | University Of Nebraska Board Of Regents | Polypeptide agonists and antagonists of human interleukin-8 |
US5602008A (en) * | 1994-11-29 | 1997-02-11 | Incyte Pharmaceuticals, Inc. | DNA encoding a liver expressed chemokine |
AU723891B2 (en) * | 1995-06-05 | 2000-09-07 | Human Genome Sciences, Inc. | Human chemokine beta-11 and human chemokine alpha-1 |
WO1996039521A1 (en) * | 1995-06-06 | 1996-12-12 | Human Genome Sciences, Inc. | Human chemokine beta-13 |
WO1996039520A1 (en) * | 1995-06-06 | 1996-12-12 | Human Genome Sciences, Inc. | Human chemokine beta-12 |
WO1997015594A1 (en) * | 1995-10-24 | 1997-05-01 | Smithkline Beecham Corporation | Novel chemokine for mobilizing stem cells |
ZA968896B (en) * | 1995-10-24 | 1997-04-24 | Smithkline Beecham Corp | Method of mobilizing hematopoietic stem cells |
AU1020997A (en) * | 1995-11-21 | 1997-06-11 | Smithkline Beecham Corporation | Method of treating sepsis |
EP0885293B1 (de) * | 1996-02-23 | 2006-06-07 | Human Genome Sciences, Inc. | Menschliche chemokin-polypeptide. |
US6509313B1 (en) * | 1996-02-28 | 2003-01-21 | Cornell Research Foundation, Inc. | Stimulation of immune response with low doses of cytokines |
AU5425496A (en) | 1996-03-18 | 1997-10-10 | Human Genome Sciences, Inc. | Chemokine alpha 3 |
JP2000508527A (ja) * | 1996-03-27 | 2000-07-11 | アイコス コーポレイション | 単球走化性タンパク質―5物質及び方法 |
US6290948B1 (en) * | 1996-05-14 | 2001-09-18 | Smithkline Beecham Corporation | Method of treating sepsis and ARDS using chamohine beta-10 |
GB9617923D0 (en) * | 1996-08-28 | 1996-10-09 | Smithkline Beecham Plc | Novel receptor |
AU4243097A (en) * | 1996-09-10 | 1998-04-02 | Schering Corporation | Mammalian chemokines, related reagents |
WO1998014573A1 (en) * | 1996-09-30 | 1998-04-09 | The General Hospital Corporation | Mcp-4 and mcp-5: novel chemokines |
-
1997
- 1997-05-06 US US08/852,212 patent/US6290948B1/en not_active Expired - Fee Related
- 1997-05-12 DE DE69721120T patent/DE69721120T2/de not_active Expired - Fee Related
- 1997-05-12 DK DK97303204T patent/DK0807439T3/da active
- 1997-05-12 EP EP97303204A patent/EP0807439B1/de not_active Expired - Lifetime
- 1997-05-14 JP JP9161779A patent/JPH1053533A/ja active Pending
-
2000
- 2000-02-01 US US09/496,273 patent/US6406688B1/en not_active Expired - Fee Related
- 2000-10-25 JP JP2000325433A patent/JP2001122801A/ja not_active Withdrawn
-
2002
- 2002-03-25 US US10/103,859 patent/US20020155094A1/en not_active Abandoned
- 2002-03-26 US US10/105,285 patent/US20020141972A1/en not_active Abandoned
- 2002-03-28 US US10/107,371 patent/US20020146390A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US6406688B1 (en) | 2002-06-18 |
JPH1053533A (ja) | 1998-02-24 |
DK0807439T3 (da) | 2003-08-11 |
US20020141972A1 (en) | 2002-10-03 |
US20020155094A1 (en) | 2002-10-24 |
US6290948B1 (en) | 2001-09-18 |
EP0807439A2 (de) | 1997-11-19 |
EP0807439B1 (de) | 2003-04-23 |
DE69721120T2 (de) | 2003-12-04 |
US20020146390A1 (en) | 2002-10-10 |
JP2001122801A (ja) | 2001-05-08 |
EP0807439A3 (de) | 1998-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69721120D1 (de) | Verwendung von menschlichen Chemokin beta-9 zur Behandlung von Atemnotsyndrom bei Erwachsenen | |
DE69726245D1 (de) | Befeuchtungsgerät zur Behandlung von Atemstillstand im Schlaf | |
DE69941566D1 (de) | N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie | |
ATE246500T1 (de) | Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege | |
ATE349428T1 (de) | Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen | |
DE69916686D1 (de) | Gerät zur Behandlung von Atemstillstand im Schlaf | |
DE69600307D1 (de) | Beatmungsgerät zur Behandlung von Ateminsuffizienzen | |
DE69830660D1 (de) | Behandlung von atemstillstand im schlaf | |
DE69631157D1 (de) | Pharmazeutische Zubereitung zur Verwendung in der Behandlung von Diabetes | |
DE69823459D1 (de) | Herzbehandlungssystem zur Feststellung und Behandlung von Herzversagen | |
DE69202207D1 (de) | Verfahren zur Herstellung von 1-Chlor-1,1,3,3,3-Pentafluorpropan und von 1,1,1,3,3,3-Hexafluorpropan. | |
DE69739303D1 (de) | Vorrichtung zur thermischen behandlung von gewebe | |
ATE214274T1 (de) | Antikonvulsiva zur verwendung bei der behandlung von amyotropischer lateralsklerose | |
DE69527313D1 (de) | Ballonkatheter zur hypertermiebehandlung | |
DE69711311D1 (de) | Vorrichtung zur thermischen Behandlung von Gewebe | |
TR199901772T2 (de) | ||
DE68910175D1 (de) | Adsorbermodul sowie Adsorberapparat zur Behandlung von Vollblut. | |
DE59206237D1 (de) | Strahlmittel, Verfahren zur Herstellung desselben sowie Verwendung des Strahlmittels | |
DE69824576D1 (de) | Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen | |
DE69216615D1 (de) | Entwässerte Blutzellen und Verfahren zur Herstellung | |
DE69734296D1 (de) | Neue dikaffeoylchinasäurederivate und deren verwendung zur behandlung von hepatitis b | |
DE69624243D1 (de) | Verwendung von unverdaulichen oligosacchariden zur vorbeugung und behandlung von mittelohrentzündung bei menschen | |
DE69531132D1 (de) | Blattförmiger Sauerstoff-Absorber und Verfahren zur Herstellung | |
DE69633985D1 (de) | Behandlung von Chromoxid und dessen Verwendung in der katalytischen Herstellung von Vinylfluorid | |
DE60027429D1 (de) | Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |